Jakobovits Aya

SEC source: 0000950170-24-100165 · ownership.xml · derivative · entry 8

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,400

Underlying: Common Stock · 26,400 shares

Expires 2033-05-31

F1 · derivative.exercise_price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof.

SEC source: 0000950170-24-100165 · ownership.xml · derivative · entry 7

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 26,400 shares

Expires 2033-05-31

F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof.

SEC source: 0000950170-24-100165 · ownership.xml · derivative · entry 6

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2032-06-01

F1 · derivative.exercise_price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof.

SEC source: 0000950170-24-100165 · ownership.xml · derivative · entry 5

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,500 shares

Expires 2032-06-01

F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof.

SEC source: 0000950170-24-100165 · ownership.xml · derivative · entry 4

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2031-04-29

F1 · derivative.exercise_price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof.

SEC source: 0000950170-24-100165 · ownership.xml · derivative · entry 3

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,500 shares

Expires 2031-04-29

F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof.

SEC source: 0000950170-24-100165 · ownership.xml · derivative · entry 2

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2030-09-16

F1 · derivative.exercise_price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof.

SEC source: 0000950170-24-100165 · ownership.xml · derivative · entry 1

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2030-09-16

F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof.

SEC source: 0000950170-24-070610 · ownership.xml · derivative · entry 5

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,400

Underlying: Common Stock · 26,400 shares

Expires 2034-06-04

F5 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0000950170-24-070610 · ownership.xml · nonDerivative · entry 1

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,800

F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0001209191-23-046093 · doc4.xml · derivative · entry 8

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,400

Underlying: Common Stock · 26,400 shares

Expires 2033-05-31

F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised.

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F5 · derivative.exercise_date: The shares subject to this option shall vest in full on the earlier to occur of (a) June 1, 2024 or (b) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.

SEC source: 0001209191-23-046093 · doc4.xml · derivative · entry 7

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 26,400 shares

Expires 2033-05-31

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F5 · derivative.exercise_date: The shares subject to this option shall vest in full on the earlier to occur of (a) June 1, 2024 or (b) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.

SEC source: 0001209191-23-046093 · doc4.xml · derivative · entry 6

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2032-06-01

F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised.

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof.

SEC source: 0001209191-23-046093 · doc4.xml · derivative · entry 5

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,500 shares

Expires 2032-06-01

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof.

SEC source: 0001209191-23-046093 · doc4.xml · derivative · entry 4

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2031-04-29

F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised.

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof.

SEC source: 0001209191-23-046093 · doc4.xml · derivative · entry 3

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,500 shares

Expires 2031-04-29

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof.

SEC source: 0001209191-23-046093 · doc4.xml · derivative · entry 2

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2030-09-16

F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised.

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on September 17, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.

SEC source: 0001209191-23-046093 · doc4.xml · derivative · entry 1

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2030-09-16

F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on September 17, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.

SEC source: 0001209191-23-033958 · doc4.xml · derivative · entry 5

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,400

Underlying: Common Stock · 26,400 shares

Expires 2033-05-31

F5 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0001209191-23-033958 · doc4.xml · nonDerivative · entry 1

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,900

F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0001209191-22-034072 · doc4.xml · derivative · entry 1

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common stock · 18,500 shares

Expires 2032-06-01

F1 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0001209191-22-018158 · doc4.xml · nonDerivative · entry 2

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 356,345

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F3 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' son is the beneficiary.

SEC source: 0001209191-22-018158 · doc4.xml · nonDerivative · entry 1

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 356,343

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F2 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' daughter is the beneficiary.

SEC source: 0001209191-22-010952 · doc4.xml · nonDerivative · entry 2

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 358,345

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.52 to $15.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' son is the beneficiary.

SEC source: 0001209191-22-010952 · doc4.xml · nonDerivative · entry 1

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 358,343

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.52 to $15.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' daughter is the beneficiary.

SEC source: 0001209191-22-009417 · doc4.xml · nonDerivative · entry 6

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 360,345

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.00 to $14.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' son is the beneficiary.

SEC source: 0001209191-22-009417 · doc4.xml · nonDerivative · entry 5

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 360,343

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.00 to $14.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' daughter is the beneficiary.

SEC source: 0001209191-22-009417 · doc4.xml · nonDerivative · entry 4

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 364,345

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.41 to $17.21. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' son is the beneficiary.

SEC source: 0001209191-22-009417 · doc4.xml · nonDerivative · entry 3

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 364,343

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.41 to $17.38. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' daughter is the beneficiary.

SEC source: 0001209191-22-009417 · doc4.xml · nonDerivative · entry 2

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 366,345

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' son is the beneficiary.

SEC source: 0001209191-22-009417 · doc4.xml · nonDerivative · entry 1

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 366,343

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' daughter is the beneficiary.

SEC source: 0001209191-22-009370 · doc5.xml · nonDerivative · entry 6

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 372,345

F6 · kind: Represents a gift of Common Stock made on December 23, 2021.

F5 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' son is the beneficiary.

SEC source: 0001209191-22-009370 · doc5.xml · nonDerivative · entry 5

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 372,343

F6 · kind: Represents a gift of Common Stock made on December 23, 2021.

F3 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' daughter is the beneficiary.

SEC source: 0001209191-22-009370 · doc5.xml · nonDerivative · entry 4

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 138,076

F6 · kind: Represents a gift of Common Stock made on December 23, 2021.

F8 · ownership.nature: Shares held in a revocable trust of which Dr. Jakobovits and her spouse are co-trustees.

SEC source: 0001209191-22-009370 · doc5.xml · nonDerivative · entry 3

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F6 · kind: Represents a gift of Common Stock made on December 23, 2021.

F7 · ownership.nature: Shares transferred from a grantor retained annuity trust ("GRAT") of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits the sole annuitant and current beneficiary. Following this transaction, this GRAT was terminated.

SEC source: 0001209191-22-009370 · doc5.xml · nonDerivative · entry 2

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 332,553

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.47 to $16.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' son is the beneficiary.

SEC source: 0001209191-22-009370 · doc5.xml · nonDerivative · entry 1

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 332,552

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.46 to $16.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' daughter is the beneficiary.

SEC source: 0001209191-21-041630 · doc4.xml · nonDerivative · entry 2

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 215,883

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $11.00 to $11.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4 · ownership.nature: Shares held in a trust of which Dr. Jakobovits spouse is the trustee and Dr. Jakobovits child is the beneficiary.

SEC source: 0001209191-21-041630 · doc4.xml · nonDerivative · entry 1

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 215,883

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $11.00 to $11.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held in a trust of which Dr. Jakobovits spouse is the trustee and Dr. Jakobovits child is the beneficiary.

SEC source: 0001209191-21-034631 · doc4.xml · nonDerivative · entry 4

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 217,806

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.00 to $14.48. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5 · ownership.nature: Shares held in a trust of which Dr. Jakobovits spouse is the trustee and Dr. Jakobovits child is the beneficiary.

SEC source: 0001209191-21-034631 · doc4.xml · nonDerivative · entry 3

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 217,807

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.00 to $14.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held in a trust of which Dr. Jakobovits spouse is the trustee and Dr. Jakobovits child is the beneficiary.

SEC source: 0001209191-21-034631 · doc4.xml · nonDerivative · entry 2

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 218,706

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.00 to $14.18. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5 · ownership.nature: Shares held in a trust of which Dr. Jakobovits spouse is the trustee and Dr. Jakobovits child is the beneficiary.

SEC source: 0001209191-21-034631 · doc4.xml · nonDerivative · entry 1

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 218,699

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.00 to $14.18. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held in a trust of which Dr. Jakobovits spouse is the trustee and Dr. Jakobovits child is the beneficiary.

SEC source: 0001209191-21-032740 · doc4.xml · nonDerivative · entry 2

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 221,806

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.05 to $13.52. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · balance_after: The Reporting Person previously transferred 149,307 shares and 149,306 shares from the trust described in footnote (7) to the trusts described in footnotes (4) and (6), respectively.

F6 · ownership.nature: Shares held in a trust of which Dr. Jakobovits spouse is the trustee and Dr. Jakobovits child is the beneficiary.

SEC source: 0001209191-21-032740 · doc4.xml · nonDerivative · entry 1

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 221,807

F1 · kind: These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.97 to $13.68. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · balance_after: The Reporting Person previously transferred 149,307 shares and 149,306 shares from the trust described in footnote (7) to the trusts described in footnotes (4) and (6), respectively.

F4 · ownership.nature: Shares held in a trust of which Dr. Jakobovits spouse is the trustee and Dr. Jakobovits child is the beneficiary.

SEC source: 0001209191-21-030100 · doc4.xml · derivative · entry 1

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2031-04-29

F1 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

SEC source: 0000899243-20-025653 · doc4.xml · derivative · entry 5

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2030-09-16

F8 · derivative.exercise_date: The shares of common stock subject to the option shall vest in equal installments on each of the thirty-six (36) monthly anniversaries of the [vesting commencement date], provided that the reporting person remains in continuous service as of the applicable vesting date.

SEC source: 0000899243-20-025653 · doc4.xml · nonDerivative · entry 4

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By grantor retained irrevocable trust.

Disclosed balance after: 77,500

F3 · price: Received in exchange for 625,000 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc." The closing price of resTORbio's common stock on the effective date of the Merger was $[ ] per share.

F7 · ownership.nature: Shares held in a trust of which Dr. Jakobovits's spouse is the trustee and Dr. Jakobovits's child is the beneficiary.

SEC source: 0000899243-20-025653 · doc4.xml · nonDerivative · entry 3

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By grantor retained irrevocable trust.

Disclosed balance after: 77,500

F3 · price: Received in exchange for 625,000 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc." The closing price of resTORbio's common stock on the effective date of the Merger was $[ ] per share.

F6 · ownership.nature: Shares held in a trust of which Dr. Jakobovits's spouse is the trustee and Dr. Jakobovits's child is the beneficiary.

SEC source: 0000899243-20-025653 · doc4.xml · nonDerivative · entry 2

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By grantor retained annuity trust.

Disclosed balance after: 135,799

F2 · price: Received in exchange for 1,095,154 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc." The closing price of resTORbio's common stock on the effective date of the Merger was $[ ] per share.

F5 · ownership.nature: Shares held in a GRAT of which Dr. Jakobovits's spouse is the trustee and Dr. Jakobovits the sole annuitant and current beneficiary.